普乐安片治疗良性前列腺增生症对比研究  

Clinical observation on therapeutic efficiency of conprata pulean in the treatment of benign prostate hyperplasia

作　　者：符伟军[1] 何学酉[1] 史立新[1] 王希友[1] 洪宝发[1] 高江平[1] 张磊[1] 杨勇[1] 宋涛[1] 

机构地区：[1]解放军总医院泌尿外科,北京100853

出　　处：《军医进修学院学报》2008年第1期6-8,共3页Academic Journal of Pla Postgraduate Medical School

摘　　要：目的:随机对照观察普乐安片治疗良性前列腺增生(BPH)的临床疗效。方法:将BPH患者80例前瞻性随机分为两组,治疗组60例,给予前列康3片,3/d口服;对照组20例,给予保列治1片,口服,一日一次;疗程均为90 d。观察治疗前后BPH患者的国际前列腺症状评分(IPSS)、生活质量评分(QOL)、前列腺体积、残余尿量及最大尿流率(Qmax)的改善情况。结果:普乐安片治疗良性前列腺增生(BPH)安全有效,总有效率为93.3%。随访观察3月,能明显改善患者主客观症状。治疗组IPSS及QOL评分由治疗前平均14.4±3.8及3.1±0.6分别下降至10.0±2.7及1.7±0.6,最大尿流率由治疗前(13.2±1.9)ml/s增加至治疗后(17.5±4.7)ml/s,治疗前后比较差异均有统计学意义(P<0.05)。治疗前后残余尿量、前列腺体积及PSA变化比较无统计学意义,治疗组与对照组治疗效果比较差异无显著意义(P>0.05)。结论:普乐安片是目前治疗症状性BPH患者的理想首选药物。Objective： To observe the therapeutic effect of the conprata pulean in the treatment of benign prostate hyper- plasia. Methods： A total of 80 patients with symptomatic benign prostatic hyperplasia were made a definite diagnosis at outpatient and randomly divided into two groups ： 60 patients of treatment group were treated with conprata pulean 3 tablet, po, tid ; 20 pa- tients in the control group, finateride with 1 tablet, po, qd ; All patients received 90 days as a course of treatment. The therapeutic results were assessed before and after the treatment by using following variables ：the safety and efficacy of conprata pulean, international prostatic symptom score （ IPSS ） , quality of life （ QOL ）, postvoid residual urine volume （ RUV ）, mean Qmax. Results： The conprata pulean was safe and effective relief for patients with obstructive BPH. The total effective rates was 93.3% in the conprata pulean group. All patients were followed up for 3months in the conprata pulean group. IPSS and QOL was decreased from 14.4 ±3.8 and 3.1 ±0.6 to 10.0 ±2.7 and 1.7±0.6, Qmax increased from 13.2 ±1.9ml/s to 17.5 ±4.7ml/s, respectively. There were significant differences of these parameters before and after treatment （ P 〈 0.05 ）, there was no signifi- cent difference between two groups （ P 〉 0. 05 ）. There were no significant differences RUV, prostate volume and PSA. Conclusion： Conprata pulean is an ideal drug in the treatment of BPH patients with obstructive symptom at present.

关 键 词：前列腺增生 普乐安 

分 类 号：R983[医药卫生—药品]